Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Posts Strong Q3 Revenue Growth; R&D, Loss Trimmed

NEW YORK, Oct.16 (GenomeWeb News) - Illumina today posted a dramatic increase in third-quarter revenues atop fallen R&D expenditures and narrowed net loss.

 

Total revenue for the period ended Sept. 28 increased to $8.2 million from $3 million one year ago, the company said. Product sales, which increased to $6.5 million in the current third quarter from $1.3 million in the year-ago period, made up the brunt of total revenues. Receipts from services in the quarter remained relatively flat at around $1 million.

 

R&D spending in the quarter fell to $5.1 million from $6.4 million in the third quarter 2002. Consequently, net loss narrowed to $5.5 million, or $.17 per share, from $7.6 million, or $.24 per share, year over year, Illumina said.

 

The company said it had around $51.2 million in cash and investments as of Sept. 28.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.